• Je něco špatně v tomto záznamu ?

Sphingosine kinase-1 predicts overall survival outcomes in non-small cell lung cancer patients treated with carboplatin and navelbine

M. Gachechiladze, T. Tichý, V. Kolek, I. Grygárková, J. Klein, G. Mgebrishvili, G. Kharaishvili, M. Janíková, P. Smičková, L. Cierna, S. Pitson, ML. Maddelein, O. Cuvillier, J. Škarda,

. 2019 ; 18 (2) : 1259-1266. [pub] 20190607

Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19035795

Sphingosine 1-phosphate (S1P) is a bioactive lipid metabolite associated with cancer cell proliferation, survival, migration and regulation of tumor angiogenesis in various cellular and animal models. Sphingosine kinase-1 (SphK1) and S1P lyase are the main enzymes that respectively control the synthesis and degradation of S1P. The present study analyzed the prognostic and predictive value of SphK1 and S1P lyase expression in patients with non-small cell lung cancer (NSCLC), treated with either surgery alone or in combination with adjuvant carboplatin and navelbine. Formalin-fixed, paraffin-embedded tissue samples from 176 patients with NSCLC were stained immunohistochemically using antibodies against SphK1 and S1P lyase, and their expression was correlated with all available clinicopathological factors. Increased expression of SphK1 was significantly associated with shorter overall and disease free survival in patients treated with adjuvant platinum-based chemotherapy. No prognostic relevance for S1P lyase expression was observed. Collectively, the results suggest that the immunohistochemical detection of SphK1 may be a promising predictive marker in NSCLC patients treated with adjuvant platinum-based chemotherapy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19035795
003      
CZ-PrNML
005      
20191015111456.0
007      
ta
008      
191007s2019 gr f 000 0|eng||
009      
AR
024    7_
$a 10.3892/ol.2019.10447 $2 doi
035    __
$a (PubMed)31423186
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Gachechiladze, Mariam $u Department of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University, 77515 Olomouc, Czech Republic.
245    10
$a Sphingosine kinase-1 predicts overall survival outcomes in non-small cell lung cancer patients treated with carboplatin and navelbine / $c M. Gachechiladze, T. Tichý, V. Kolek, I. Grygárková, J. Klein, G. Mgebrishvili, G. Kharaishvili, M. Janíková, P. Smičková, L. Cierna, S. Pitson, ML. Maddelein, O. Cuvillier, J. Škarda,
520    9_
$a Sphingosine 1-phosphate (S1P) is a bioactive lipid metabolite associated with cancer cell proliferation, survival, migration and regulation of tumor angiogenesis in various cellular and animal models. Sphingosine kinase-1 (SphK1) and S1P lyase are the main enzymes that respectively control the synthesis and degradation of S1P. The present study analyzed the prognostic and predictive value of SphK1 and S1P lyase expression in patients with non-small cell lung cancer (NSCLC), treated with either surgery alone or in combination with adjuvant carboplatin and navelbine. Formalin-fixed, paraffin-embedded tissue samples from 176 patients with NSCLC were stained immunohistochemically using antibodies against SphK1 and S1P lyase, and their expression was correlated with all available clinicopathological factors. Increased expression of SphK1 was significantly associated with shorter overall and disease free survival in patients treated with adjuvant platinum-based chemotherapy. No prognostic relevance for S1P lyase expression was observed. Collectively, the results suggest that the immunohistochemical detection of SphK1 may be a promising predictive marker in NSCLC patients treated with adjuvant platinum-based chemotherapy.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Tichý, Tomáš $u Department of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University, 77515 Olomouc, Czech Republic.
700    1_
$a Kolek, Vítězslav $u Department of Tuberculosis and Respiratory Diseases, Faculty of Medicine and Dentistry, Palacký University and Faculty Hospital in Olomouc, 77900 Olomouc, Czech Republic.
700    1_
$a Grygárková, Ivona $u Department of Tuberculosis and Respiratory Diseases, Faculty of Medicine and Dentistry, Palacký University and Faculty Hospital in Olomouc, 77900 Olomouc, Czech Republic.
700    1_
$a Klein, Jiří $u 1st Department of Surgery, Faculty of Medicine and Dentistry, Palacký University and Faculty Hospital in Olomouc, 77900 Olomouc, Czech Republic.
700    1_
$a Mgebrishvili, Giorgi $u Department of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University, 77515 Olomouc, Czech Republic.
700    1_
$a Kharaishvili, Gvantsa $u Department of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University, 77515 Olomouc, Czech Republic.
700    1_
$a Janíková, Mária $u Department of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University, 77515 Olomouc, Czech Republic.
700    1_
$a Smičková, Petra $u Department of Tuberculosis and Respiratory Diseases, Faculty of Medicine and Dentistry, Palacký University and Faculty Hospital in Olomouc, 77900 Olomouc, Czech Republic.
700    1_
$a Cierna, Lucia $u Faculty of Medicine and Dentistry, Palacký University Olomouc, 77515 Olomouc, Czech Republic.
700    1_
$a Pitson, Stuart $u Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide SA5000, Australia.
700    1_
$a Maddelein, Marie-Lise $u Institut de Pharmacologie et de Biologie Structurale, Université de Toulouse, CNRS, UPS, 31077 Toulouse, France.
700    1_
$a Cuvillier, Olivier $u Institut de Pharmacologie et de Biologie Structurale, Université de Toulouse, CNRS, UPS, 31077 Toulouse, France. Equipe Labellisée Ligue contre le Cancer, 75013 Paris, France.
700    1_
$a Škarda, Jozef $u Department of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University, 77515 Olomouc, Czech Republic.
773    0_
$w MED00193499 $t Oncology letters $x 1792-1074 $g Roč. 18, č. 2 (2019), s. 1259-1266
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31423186 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20191015111921 $b ABA008
999    __
$a ind $b bmc $g 1452455 $s 1074345
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 18 $c 2 $d 1259-1266 $e 20190607 $i 1792-1074 $m Oncology letters $n Oncol Lett $x MED00193499
LZP    __
$a Pubmed-20191007

Najít záznam

Citační ukazatele

Možnosti archivace